<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158937</url>
  </required_header>
  <id_info>
    <org_study_id>REB#08-316</org_study_id>
    <nct_id>NCT01158937</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients</brief_title>
  <official_title>Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patient With Exacerbation of Pulmonary Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Meropenem is an intravenous antibiotic commonly used to treat acute exacerbation of&#xD;
      respiratory infections in cystic fibrosis. The research study aims to determine if a&#xD;
      different method of infusing the drug over 3 hours or longer, instead of the traditional&#xD;
      half-hour will improve target attainment of drug concentrations and bactericidal activity. A&#xD;
      secondary aim is to assess if the pharmacokinetics of meropenem is different during active&#xD;
      infection compared to non-infective stage. Twelve patients admitted with acute respiratory&#xD;
      infection and who requires meropenem will be enrolled into the study. Meropenem blood&#xD;
      concentrations collected over 8 hours will be measured after half-hour and 3-hour infusions&#xD;
      on different days. A pharmacokinetic modelling and Monte Carlo simulation program will use&#xD;
      the data to assess and predict the optimal method of dosing. When patients return for a&#xD;
      follow-up clinic visit, a single dose of meropenem will be administered and blood&#xD;
      concentrations will be measured to determine the pharmacokinetics during non-infective stage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Meropenem plays a crucial role in the treatment of pulmonary exacerbations in cystic fibrosis&#xD;
      patients, because it has activity against both P. aeruginosa and B. cepacia, two of the most&#xD;
      problematic pathogens that are encountered in this disease. These organisms cause chronic&#xD;
      endobronchitis with frequent exacerbations which lead to significant morbidity and premature&#xD;
      mortality. Treatment options for pulmonary exacerbations are limited due to the high rates of&#xD;
      resistance with currently available antibiotics and lack of development of new effective&#xD;
      antibiotics. Therefore optimization of the dosing of meropenem, by use of extended infusion&#xD;
      strategy, is one method to allow us to maximize the efficacy of this drug. Meropenem is a&#xD;
      beta-lactam type antibiotic with time-dependent bactericidal activity and hence it is&#xD;
      suitable for extended infusion dosing. The key rationale for extended infusion of beta-lactam&#xD;
      antibiotics is to allow for optimization of pharmacodynamic target attainment of time above&#xD;
      the minimal inhibitory concentrations (T&gt;MIC) to maximize bactericidal killing and optimize&#xD;
      clinical outcomes. The use of this infusion strategy has been studied in non-cystic fibrosis&#xD;
      patients treated primarily with piperacillin-tazobactam or meropenem for P. aeruginosa&#xD;
      infections. The application of this strategy in cystic fibrosis patients has not been well&#xD;
      studied, and there is no data for the treatment of B. cepacia infections. Also the&#xD;
      pharmacokinetic characteristics of meropenem in adult cystic fibrosis patients with pulmonary&#xD;
      exacerbation have not been previously studied. It is unclear whether or not the&#xD;
      pharmacokinetic profile of meropenem in patients without exacerbation can be accurately&#xD;
      extrapolated to those patients with exacerbation. The first phase of this study will,&#xD;
      therefore, describe the pharmacokinetic profile of meropenem and the distribution of MICs for&#xD;
      P. aeruginosa and B. cepacia in a population of adult cystic fibrosis patients with pulmonary&#xD;
      exacerbation. The data will be used to determine an optimal extended infusion dosing strategy&#xD;
      specifically for our patients with cystic fibrosis. The second phase of our study will&#xD;
      provide additional data on the pharmacokinetics of meropenem in patients without active&#xD;
      infection.&#xD;
&#xD;
      Significance of study:&#xD;
&#xD;
      This study will provide new information regarding the pharmacokinetics of meropenem in a&#xD;
      population of cystic fibrosis patients with pulmonary exacerbation. This will allow us to&#xD;
      apply Monte Carlo simulation to the data set with greater confidence as it directly reflects&#xD;
      our own target population. Optimization of meropenem dosing based on pharmacodynamic profile&#xD;
      and Monte Carlo simulation lays the groundwork for clinical efficacy studies in the future.&#xD;
      Based on results from previous studies, optimization of meropenem dosing has the potential to&#xD;
      produce better patient outcomes, reduce drug utilization and cost and reduce rates of&#xD;
      resistance. These can be examined in future clinical studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate enrolment and lack of resources&#xD;
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile of extended infusion meropenem in Cystic Fibrosis</measure>
    <time_frame>Two x eight hour pharmacokinetic monitoring periods (carried over 2 days).</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Cystic Fibrosis Pulmonary Exacerbation</condition>
  <arm_group>
    <arm_group_label>Extended Meropenem Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meropenem Infusion over 3 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bolus Meropenem Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meropenem infusion over 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem Infusion</intervention_name>
    <description>Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)</description>
    <arm_group_label>Bolus Meropenem Infusion</arm_group_label>
    <arm_group_label>Extended Meropenem Infusion</arm_group_label>
    <other_name>Meropenem or Merrem(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years old,&#xD;
&#xD;
          -  currently experiencing new or exacerbation of active pulmonary infection as evidenced&#xD;
             by increased coughing, sputum production, wheezing, white blood count and/or fever,&#xD;
&#xD;
          -  requires meropenem for treatment,&#xD;
&#xD;
          -  recent sputum culture positive for P. aeruginosa and/or B. cepacia at a prior visit,&#xD;
&#xD;
          -  be able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypersensitivity and/or intolerance to meropenem,&#xD;
&#xD;
          -  history of seizures,&#xD;
&#xD;
          -  current use of valproic acid,&#xD;
&#xD;
          -  significant psychiatric illness,&#xD;
&#xD;
          -  contraindication to insertion of a venous catheter,&#xD;
&#xD;
          -  worsening of clinical status requiring admission to intensive care unit (ICU),&#xD;
&#xD;
          -  creatinine clearance ≤50 ml/min,&#xD;
&#xD;
          -  significant cystic fibrosis-related liver dysfunction characterized by portal&#xD;
             hypertension and cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Cortes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>July 7, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meropenem</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>extended infusion</keyword>
  <keyword>pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

